Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 158,600 shares, a decline of 21.7% from the February 28th total of 202,600 shares. Approximately 3.9% of the company’s stock are short sold. Based on an average daily volume of 377,700 shares, the short-interest ratio is currently 0.4 days.

Virax Biolabs Group Price Performance

VRAX opened at $1.14 on Tuesday. The stock has a fifty day moving average price of $1.63 and a 200 day moving average price of $1.89. Virax Biolabs Group has a 1 year low of $0.60 and a 1 year high of $9.00.

Institutional Investors Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd acquired a new stake in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright initiated coverage on shares of Virax Biolabs Group in a research report on Monday. They issued a “buy” rating and a $3.00 target price for the company.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.